Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer

Molecular Imaging and Biology

Volumn 4, Issue 1, 2002, Pages 99-104

  Oyama, Nobuyuki ^a,b   Akino, Hironobu ^a   Suzuki, Yuji ^a   Kanamaru, Hiroshi ^a   Miwa, Yoshiji ^a   Tsuka, Harutoshi ^a   Sadato, Norihiro ^a   Yonekura, Yoshiharu ^a   Okada, Kenichiro ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FDG PET; Glucose metabolism; Prognosis; Prostate cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; IMAGING SYSTEM; KAPLAN MEIER METHOD; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 0036203470     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1095-0397(01)00065-6     Document Type: Article

References (24)

1. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate
2. Current prognostic factors for prostate carcinoma
3. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumor
4. Bone metastases: Improving the therapeutic index
5. Clinical trials in relapsed prostate cancer: Defining the target
6. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
7. Prediction of survival in glioma patients by means of positron emission tomography
8. Use of positron emission tomography with fluorodeoxyglucose in patient with extracranial head and neck cancers
9. Glucose utilization in vivo by human pulmonary neoplasms
10. F-18-FDG-PET in pancreatic cancer: An unsolved problem
11. 18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
12. The prognostic significane of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
13. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2- fluoro[18F]-d-glucose
14. Prognostic value of FDG PeT imaging in malignant pleural mesothelioma
15. The increase of accumulation of 18-fluorodeoxyglucose in untreated prostate cancer
16. Histologic grading and clinical staging of carcinoma of the prostate in urologic pathology
17. Efficient stereospecific synthesis of no-carried-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
18. Performance characteristics of whole-body PET scanner
19. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose
20. F-18 FDG PET for differentiation of local recurrent prostate cancer and scar
21. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose
22. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by FDG-PET whole body scanning
23. Positron emission tomography of a human prostate xenograft: Association of changes in deoxyglucose accumulation with other Measures of outcome following androgen withdrawal